LifeMD, Inc. LFMD
is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients
to access virtual medical care and pharmacy services. We believe the traditional healthcare model requiring patients to visit a physician's
office, travel to a retail pharmacy, and return for follow-up appointments or prescription refills is complex, inefficient, and costly
which can discourage individuals from seeking necessary medical care and medications. At the same time, the United States ("U.S.")
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $194.1M | $154.8M | $152.5M | $119.0M | $92.9M | $37.3M | $12.5M | $42.5K | $23.2K | $5.2M |
| Cost of revenue | $27.7M | $21.4M | $18.9M | $18.7M | $18.0M | $8.9M | $2.5M | $2.0M | $1.0M | $1.9M |
| Gross profit | $166.3M | $133.4M | $133.6M | $100.4M | $74.9M | $28.4M | $9.9M | $6.3M | $2.7M | $3.3M |
| SG&A | $57.9M | $57.9M | $51.7M | $47.0M | $39.5M | $45.0M | $2.4M | $2.3M | $742.0K | $1.0M |
| Total operating expenses | $174.0M | $153.8M | $148.1M | $143.8M | $129.2M | $86.3M | $12.8M | $8.4M | $3.9M | $4.5M |
| Operating income | -$7.7M | -$20.4M | -$14.5M | -$43.4M | -$54.3M | -$57.8M | -$2.9M | -$2.1M | -$1.2M | -$1.2M |
| Interest expense | $1.4M | $2.2M | $2.6M | $1.3M | $3.0M | $1.7M | $761.1K | $354.4K | $100.5K | $48.6K |
| Pre-tax income | -$10.2M | -$22.6M | -$17.4M | -$44.7M | -$61.3M | -$60.4M | -$3.7M | -$2.4M | -$1.4M | -$1.2M |
| Income tax | $45.7K | $598.0K | $428.0K | $360.7K | $7.7K | $122.5K | $122.5K | $124.7K | — | — |
| Net income | -$11.2M | $24.5M | $17.8M | -$45.5M | -$60.9M | -$58.6M | -$3.1M | -$1.2M | -$1.2M | -$1.1M |
| EPS, basic | 0.25 | -0.60 | — | — | — | — | — | — | -0.03 | -0.03 |
| EPS, diluted | 0.25 | -0.60 | — | — | — | — | — | — | -0.03 | -0.03 |
| Shares, diluted (wtd. avg.) | $45.1M | $41.2M | $33.9M | $31.0M | $27.0M | $14.3M | $9.9M | $44.2M | $41.7M | $33.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $36.8M | $32.7M | $33.1M | $4.0M | $41.3M | $9.2M | $1.1M | $180.1K | $141.4K | $182.6K |
| Receivables | $9.3M | $10.5M | $5.3M | $2.8M | $980.1K | $997.8K | $97.4K | $99.1K | $128.2K | $444.7K |
| Inventory | $2.8M | $2.8M | $2.8M | $3.7M | $1.6M | $1.3M | $950.1K | $1.0M | $681.3K | $160.3K |
| Total current assets | $51.8M | $52.4M | $42.6M | $11.3M | $44.9M | $12.4M | $2.7M | $1.6M | $1.3M | $789.8K |
| Property, plant and equipment | $2.4M | $1.4M | $476.3K | $476.4K | $233.8K | — | — | — | — | — |
| Goodwill | — | — | — | $8.0M | $0 | — | — | — | — | — |
| Other intangibles | $262.3K | $53.3K | $3.0M | $3.8M | $19.8K | $339.8K | $675.5K | $1.0M | — | — |
| Total assets | $70.4M | $76.1M | $58.5M | $25.7M | $49.9M | $13.4M | $3.4M | $2.6M | $1.3M | $789.8K |
| Accounts payable | $14.1M | $10.9M | $11.1M | $10.1M | $9.1M | $10.4M | $3.1M | $869.0K | $422.3K | $752.9K |
| Total current liabilities | $41.6M | $67.4M | $34.8M | $31.4M | $22.8M | $13.9M | $4.0M | $1.2M | $641.0K | $1.2M |
| Total liabilities | $47.3M | $83.7M | $52.9M | $33.0M | $24.1M | $14.2M | $4.6M | $1.8M | $641.0K | — |
| Retained earnings | -$228.6M | -$239.9M | -$214.3M | -$190.6M | -$141.9M | -$80.2M | -$16.6M | -$12.1M | -$10.9M | -$9.7M |
| Total equity | $23.2M | -$9.1M | $4.2M | -$11.9M | $21.7M | -$4.5M | -$1.1M | $819.7K | $622.8K | -$361.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.3M | $17.5M | $8.8M | -$22.9M | -$33.1M | -$12.1M | $251.4K | -$905.5K | -$817.2K | -$407.9K |
| Depreciation and amortisation | $865.5K | $465.8K | $204.0K | $161.9K | $13.6K | — | — | — | — | — |
| Stock-based compensation | $10.5M | $12.2M | $12.5M | $13.7M | $12.1M | $18.7M | $733.2K | $273.6K | $162.7K | $588.0K |
| Capital expenditure | $1.9M | $1.5M | $203.8K | $366.6K | $247.4K | — | — | — | — | — |
| Investing cash flow | $6.9M | -$11.5M | -$8.7M | -$13.9M | -$3.4M | -$798.1K | -$100.0K | $141.4K | — | — |
| Financing cash flow | -$13.4M | -$4.1M | $29.1M | -$528.2K | $68.6M | $21.0M | $775.1K | $802.8K | $776.0K | $357.5K |
| Dividends paid | $3.1M | $3.1M | $3.1M | $3.1M | $871.5K | — | — | — | — | — |
| Buybacks | $270.0K | — | — | — | — | — | — | — | $76.6K | $87.1K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020419.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | $6.42B | 54.3x | 59.0% |
| TDOC | Teladoc Health, Inc. | $1.14B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $604.4M | — | 27.8% |
| SBC | SBC Medical Group Holdings Inc | $423.7M | 8.2x | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | $201.5M | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | — | — | 26.6% |
| BMGL | Basel Medical Group Ltd | — | — | — |